Axovant Sciences Ltd (NASDAQ:AXGT) gapped down prior to trading on Friday . The stock had previously closed at $1.36, but opened at $1.42. Axovant Sciences shares last traded at $1.40, with a volume of 46934 shares.

Several brokerages have commented on AXGT. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Axovant Sciences in a research report on Tuesday, March 12th. JMP Securities reiterated an “outperform” rating and issued a $6.00 price target (down from $8.00) on shares of Axovant Sciences in a research report on Monday, March 11th. Chardan Capital upgraded shares of Axovant Sciences from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Monday, March 11th. Finally, Guggenheim began coverage on shares of Axovant Sciences in a research report on Friday, February 15th. They issued a “buy” rating and a $7.00 price target on the stock.

The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $220.89 million, a P/E ratio of -0.69 and a beta of 1.33.

Axovant Sciences (NASDAQ:AXGT) last issued its quarterly earnings results on Thursday, February 7th. The company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27). As a group, sell-side analysts expect that Axovant Sciences Ltd will post -1.23 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Axovant Sciences (AXGT) Shares Gap Down to $1.42” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2019/03/17/axovant-sciences-axgt-shares-gap-down-to-1-42.html.

Axovant Sciences Company Profile (NASDAQ:AXGT)

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics in the fields of neurology and psychiatry. Its therapeutic focus are Parkinson’s Disease and Lewy Body Dementia. It operates through the following geographical sgements: United States, Switzerland, Bermuda, and Other.

Read More: Is the QQQ ETF safe?

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.